Stefania Cuzzubbo
YOU?
Author Swipe
View article: P05.13.A DECIPHERING GLIOBLASTOMA METABOLIC SIGNATURE: MOLECULAR PROFILING AND NADH-FLIM IMAGING
P05.13.A DECIPHERING GLIOBLASTOMA METABOLIC SIGNATURE: MOLECULAR PROFILING AND NADH-FLIM IMAGING Open
INTRODUCTION Recent breakthroughs in single-cell analysis reveal distinct metabolic cellular states of glioblastoma (GBM) and allow the detection of GBMs which are dependent on oxidative phosphorylation (OXPHOS). The aims of the study was …
View article: KS04.6.A A PHASE II STUDY OF AN ANTI-TERT VACCINE (UCPVAX) WITH OR WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA
KS04.6.A A PHASE II STUDY OF AN ANTI-TERT VACCINE (UCPVAX) WITH OR WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA Open
BACKGROUND UCPVax is a therapeutic vaccine designed to elicit CD4⁺ helper T-cell responses targeting telomerase (TERT), a tumor-associated antigen in glioblastoma (GBM). Temozolomide (TMZ) is known to induce CD4⁺ T-cell lymphopenia, potent…
View article: P12.59.B CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE
P12.59.B CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE Open
BACKGROUND The median overall survival of patients with an IDH-mutant high-grade gliomas (IDHm HGGs), including grade 3 oligodendroglioma (O3), grade 3 and 4 astrocytoma (A3, A4), is well known. While this clinical information is useful at…
View article: P08.12.B NAVIG-1: A PHASE I/IIA STUDY EVALUATING AN ANTI-TELOMERASE IMMUNOTHERAPY IN GLIOBLASTOMA
P08.12.B NAVIG-1: A PHASE I/IIA STUDY EVALUATING AN ANTI-TELOMERASE IMMUNOTHERAPY IN GLIOBLASTOMA Open
BACKGROUND Glioblastoma remains the most lethal brain tumor despite standard therapies, which include surgery, radiotherapy and chemotherapy. Immunotherapies, such as peptide vaccines, offer a promising strategy; however commonly used form…
View article: P08.18.B PROSPECTIVE EVALUATION OF NEUROLOGICAL SAFETY AFTER ANTI-BCMA CAR T-CELL THERAPY IN A SINGLE-CENTRE COHORT
P08.18.B PROSPECTIVE EVALUATION OF NEUROLOGICAL SAFETY AFTER ANTI-BCMA CAR T-CELL THERAPY IN A SINGLE-CENTRE COHORT Open
BACKGROUND Anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cell therapy has demonstrated high efficacy in patients with relapsed/refractory multiple myeloma (R/R MM). Acute toxicities, including cytokine release syn…
View article: Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of <scp>ICANS</scp> in <scp>CAR</scp> T‐Cell Therapy for Aggressive B‐Cell Lymphoma
Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of <span>ICANS</span> in <span>CAR</span> T‐Cell Therapy for Aggressive B‐Cell Lymphoma Open
Background Immune effector cell‐associated neurotoxicity syndrome (ICANS) is a common, serious complication of CAR T‐cell therapy for blood cancers. This study evaluates the impact of baseline cognitive status and pre‐existing neurological…
View article: REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas Open
View article: P06.14.A DIAGNOSIS AND MANAGEMENT OF NEUROPATHIES RELATED TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES
P06.14.A DIAGNOSIS AND MANAGEMENT OF NEUROPATHIES RELATED TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES Open
BACKGROUND Immune checkpoint inhibitors (ICIs) are associated with a wide range of neurotoxicities. Several types of neuropathies have been associated to immune checkpoint inhibitors (ICIs), from length-dependent sensory neuropathies to ra…
View article: KS02.5.A OVERALL SURVIVAL ASSOCIATED WITH FIRST-LINE PCV OR TEMOZOLOMIDE IN COMBINATION WITH RADIOTHERAPY IN PATIENTS WITH IDH-MUTANT, 1P/19Q CODELETED, GRADE 3 OLIGODENDROGLIOMA: ANALYSIS FROM THE POLA COHORT
KS02.5.A OVERALL SURVIVAL ASSOCIATED WITH FIRST-LINE PCV OR TEMOZOLOMIDE IN COMBINATION WITH RADIOTHERAPY IN PATIENTS WITH IDH-MUTANT, 1P/19Q CODELETED, GRADE 3 OLIGODENDROGLIOMA: ANALYSIS FROM THE POLA COHORT Open
BACKGROUND Patients with IDH-mutant, 1p/19q codeleted, grade 3 oligodendroglioma (Olig-3) derive benefit from the addition of alkylating agent chemotherapy to radiotherapy. However, to date, the choice between Procarbazine, Lomustine, and …
View article: KS01.6.A UCPVAX-GLIO: A PHASE II TRIAL EVALUATING THE IMMUNOGENICITY AND EFFICACY OF AN ANTI-TELOMERASE VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GBM
KS01.6.A UCPVAX-GLIO: A PHASE II TRIAL EVALUATING THE IMMUNOGENICITY AND EFFICACY OF AN ANTI-TELOMERASE VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GBM Open
BACKGROUND The Telomerase Reverse Transcriptase (TERT) is activated in 85%-90% of cancers, and glioblastomas (GBM) harbor the highest incidence of activating mutations within its promoter (over 85% of patients). This high expression of TER…
View article: P06.17.A OPTIC NEUROPATHY RELATED TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES
P06.17.A OPTIC NEUROPATHY RELATED TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES Open
BACKGROUND Immune checkpoint inhibitors (ICIs) are associated with a broad spectrum of neurotoxicities. ICI-related optic neuritis have been rarely reported and poorly described. However, their knowledge is essential to promptly recognise …
View article: Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma
Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma Open
PURPOSE The Lynch syndrome (LS)-glioma association is poorly documented. As for mismatch repair deficiency (MMRd) in glioma, a hallmark of LS-associated tumors, there are only limited data available. We determined MMRd and LS prevalence in…
View article: Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy
Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy Open
We previously reported that a novel peptide vaccine platform, based on synthetic melanin nanoaggregates, triggers strong cytotoxic immune responses and significantly suppresses tumor growth in mice. However, the mechanisms underlying such …
View article: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Open
In conclusion, no significant neurocognitive or neurologic disorders were observed in this cohort of patients, 2 years after treatment with anti-CD19 CAR T cells.
View article: Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study
Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study Open
Background Chimeric antigen receptor-modified T (CAR T) cells are profoundly changing the standard of care in B-cell malignancies. This new therapeutic class induces a significant number of acute neurotoxicity, but data regarding mid- and …
View article: Applications of Melanin and Melanin-Like Nanoparticles in Cancer Therapy: A Review of Recent Advances
Applications of Melanin and Melanin-Like Nanoparticles in Cancer Therapy: A Review of Recent Advances Open
Thanks to the growing knowledge about cancers and their interactions with the immune system, a huge number of therapeutic cancer vaccines have been developed in the past two decades. Despite encouraging results in pre-clinical models, canc…
View article: Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) Open
PURPOSE TP53-mutated ( TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete remission [CR]) with azacitidine (AZA) alon…
View article: Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments
Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments Open
Although the discovery and characterization of multiple tumor antigens have sparked the development of many antigen/derived cancer vaccines, many are poorly immunogenic and thus, lack clinical efficacy. Adjuvants are therefore incorporated…
View article: Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment Open
Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor and has a very poor prognosis, with only around 5% of patients surviving for a period of 5 years or more after diagnosis. Despite aggressive multimodal ther…
View article: Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases
Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases Open
Importance: Few data are available on patients with leptomeningeal disease (LM) from melanoma treated with new systemic therapies. Objective: To gain a better understanding of patients, disease characteristics, and therapeutic intervention…
View article: Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients Open
Immune-checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated antigen-4 and programmed cell death ligand-1) are associated with several immune-related neurological disorders. Cases of meningitis related to ICIs are poorly…
View article: The adjuvant effect of melanin is superior to incomplete Freund’s adjuvant in subunit/peptide vaccines in mice
The adjuvant effect of melanin is superior to incomplete Freund’s adjuvant in subunit/peptide vaccines in mice Open
View article: P14.31 CMV reactivation in a cohort of newly-diagnosed glioblastoma patients treated with temozolomide chemoradiotherapy. A single center analysis
P14.31 CMV reactivation in a cohort of newly-diagnosed glioblastoma patients treated with temozolomide chemoradiotherapy. A single center analysis Open
BACKGROUND The Cytomegalovirus (CMV) is a ubiquitous herpes virus which infects 60–80 % of the population in Europe. Although the CMV usually remains latent, reactivation can occur in the context of an immunodepression, such as low CD4-lym…
View article: Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma—a randomised multicentre trial (ASTER trial). An ANOCEF study
Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma—a randomised multicentre trial (ASTER trial). An ANOCEF study Open
Losartan, although well tolerated, does not reduce the steroid requirement in newly diagnosed GBM patients treated with concomitant RT and TMZ. Trial registration number NCT01805453 with ClinicalTrials.gov.
View article: P01.074 Interest of QuID-7 for insular localization gliomas
P01.074 Interest of QuID-7 for insular localization gliomas Open
Although insular infiltration by gliomas is relatively common, the related symptomatology is poorly known and therefore often undiagnosed. To better diagnose insular signs with a new designed questionnaire: the QuID -7. The QuID 7 covers 7…
View article: P05.76 Resuming treatment with immune checkpoint inhibitors in cancer patients who developed immune-related meningitis
P05.76 Resuming treatment with immune checkpoint inhibitors in cancer patients who developed immune-related meningitis Open
Immune checkpoint inhibitors (ICIs) targeting CTLA-4 (Cytotoxic T-lymphocyte associated antigen 4) and PD-1 (Programmed cell death ligand 1) constitute a promising class of cancer treatment but are associated with several immune-related di…
View article: OS2.4 Angiotensin II Receptor Blockers, steroids and radiotherapy in glioblastoma - A randomized multicenter trial (ASTER Trial). An ANOCEF Study
OS2.4 Angiotensin II Receptor Blockers, steroids and radiotherapy in glioblastoma - A randomized multicenter trial (ASTER Trial). An ANOCEF Study Open
Glioblastomas, the most common primary central nervous system tumors, induce a peritumoral vasogenic edema impairing functional status and quality of life. Steroids reduce brain tumor-related edema, but are associated with numerous side ef…
View article: Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 <sup>+</sup> T cell activation in the presence of adjuvant temozolomide
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 <sup>+</sup> T cell activation in the presence of adjuvant temozolomide Open
In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Three intr…
View article: P04.08 Neurological adverse events associated with the immune checkpoint inhibitors: review of the literature and characterization of the neurological patterns
P04.08 Neurological adverse events associated with the immune checkpoint inhibitors: review of the literature and characterization of the neurological patterns Open
INTRODUCTION: Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies) constitute a promising class of cancer treatment, but they are associated with several immune-related adverse events (irAEs). Common grade 3/4 ir…
View article: IMCT-06SURVIVAL GAIN AND IMMUNE RESPONSE IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL IMMUNOTHERAPY BEFORE AND DURING ADJUVANT TEMOZOLOMIDE
IMCT-06SURVIVAL GAIN AND IMMUNE RESPONSE IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL IMMUNOTHERAPY BEFORE AND DURING ADJUVANT TEMOZOLOMIDE Open
Dendritic cell (DC) immunotherapy is gaining momentum in clinical cancer immunotherapy.We set-up a phase I-II study in patients with first diagnosis of glioblastoma (GBM) in which DC immunotherapy was associated to standard radiochemothera…